Tromsø

WP4: Advancing oncological PET imaging using machine learning

By kjm / 10. September 2020 / Comments Off on WP4: Advancing oncological PET imaging using machine learning

The work package on machine learning will develop data analysis methods in support of the other work packages. The aim is to use expertise in artificial intelligence to help solving the medical research questions in the 180° North project. Our work focuses in particular on how to fuse the information from data acquisitions with PET,…

Read More

WP3: Phagocyte targeting in breast cancer

By kjm / 10. September 2020 / Comments Off on WP3: Phagocyte targeting in breast cancer

In spite of an enormous global research effort, astonishing preclinical cancer cures, and the approval of multiple formulations, nanomedicine’s impact on cancer patient care remains limited. Recently, it is becoming evident that this unsatisfactory exploitation may be tackled by considering nanodrugs’ extensive interaction with the immune system. Moreover, our collaborators recently demonstrated these interactions can…

Read More

WP2: Radionuclide targeted therapy and imaging in Glioblastoma

By kjm / 10. September 2020 / Comments Off on WP2: Radionuclide targeted therapy and imaging in Glioblastoma

The plasticity of GB tumor cells and their ability to infiltrate adjoining brain tissue limits the effectiveness of current cancer therapies. Microglia plays an important role in GB progression. Inhibition of EGFR and CSF-1R decreases microglia-stimulated invasion of GB cells. Specific radiopharmaceuticals targeting EGFR or CSF-1R will be developed (WP3/Bergen) and applied as (i) diagnostic…

Read More

WP1: Immuno-PET and lung cancer

By kjm / 10. September 2020 / Comments Off on WP1: Immuno-PET and lung cancer

Despite the demonstrated effectiveness of immunoregulatory agents such as immune checkpoint blockers (ICB) on refractory cancers, these therapies work satisfactorily only in a reduced subset of patients. Further, ICB treatments are not exempt of risks and are associated to very high costs. Reliable response biomarkers are needed to identify responders and non-responders, and conventional imaging…

Read More